Keros Therapeutics (KROS) Other Non Operating Income (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Other Non Operating Income came in at $273000.0 in Q4 2025, up 219.21% YoY from $85522.6 in Q4 2024, and up 207.91% on a QoQ basis from -$253000.0 in Q3 2025.
Keros Therapeutics (KROS) Other Non Operating Income (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Other Non Operating Income data on file, last reported at $273000.0 in Q4 2025.
- Quarterly Other Non Operating Income rose 219.21% year-over-year to $273000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$539000.0 (up 43.5% YoY) and the FY2025 annual result came in at -$539000.0, up 43.5% from the prior year.
- Other Non Operating Income improved to $273000.0 in Q4 2025, from -$253000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $762000.0 in Q3 2022 to a low of -$1.4 million in Q4 2022.
- A 5-year average of -$134750.0 and a median of -$96500.0 in 2021 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 656.2% in 2022, down 1288.12% in 2022.
- Tracing KROS's Other Non Operating Income over 5 years: stood at -$101000.0 in 2021, then slumped by 1288.12% to -$1.4 million in 2022, then jumped by 103.99% to $56000.0 in 2023, then sank by 508.93% to -$229000.0 in 2024, then jumped by 219.21% to $273000.0 in 2025.
- The last three Other Non Operating Income figures came in at $273000.0 (Q4 2025), -$253000.0 (Q3 2025), and -$221000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60,000.00 |
| Dec 31, 2025 | 273,000.00 |
| Sep 30, 2025 | -253,000.00 |
| Jun 30, 2025 | -221,000.00 |
| Mar 31, 2025 | -338,000.00 |
| Dec 31, 2024 | -229,000.00 |
| Sep 30, 2024 | -92,000.00 |
| Jun 30, 2024 | -196,000.00 |
| Mar 31, 2024 | -437,000.00 |
| Dec 31, 2023 | 56,000.00 |
| Sep 30, 2023 | -67,000.00 |
| Jun 30, 2023 | -155,000.00 |
| Mar 31, 2023 | -40,000.00 |
| Dec 31, 2022 | -1.40 Mn |
| Sep 30, 2022 | 762,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Mar 31, 2022 | -59,000.00 |
| Dec 31, 2021 | -101,000.00 |
| Sep 30, 2021 | -137,000.00 |
| Jun 30, 2021 | -80,000.00 |